Form 4: Medtronic CAO Denise Blomquist Equity Settlement

Medtronic Chief Accounting Officer Denise Blomquist acquired 1,712 ordinary shares following the settlement of performance-vesting share units.

Summary

• Denise L. Blomquist, Chief Accounting Officer of Medtronic plc, reported the acquisition of 1,712 ordinary shares.
• The transaction occurred on May 26, 2026, via the settlement of performance-vesting share units granted on July 31, 2023.
• Following this transaction, the reporting person holds a total of 14,974 ordinary shares directly.
• Of the shares acquired, 1,027 are subject to deferred delivery until the reporting person's employment with the company ends.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine regulatory disclosure regarding executive equity compensation with no impact on company operations or financial strategy.

Positives

• The transaction reflects the successful vesting of performance-based equity incentives, aligning management interests with long-term shareholder value.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The filing does not provide forward-looking financial guidance, as it is a standard disclosure of insider equity transactions.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation settlement, common among large-cap medical device companies to ensure transparency in management equity holdings.

Comparison to Industry Standards

• The equity settlement structure is consistent with standard executive compensation practices at major healthcare firms like Abbott Laboratories and Boston Scientific.

Stakeholder Impact

• Minimal impact on stakeholders as this is a standard internal equity settlement.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Medtronic, MDT, Form 4, Insider Trading, Equity Compensation, Chief Accounting Officer